Pharvaris NV- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Pharvaris NV 公司

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Pharvaris NV簡介



公司代碼PHVS

公司名稱Pharvaris NV

上市日期Feb 05, 2021

CEOModig (Berndt B.A.E)

員工數量- -

證券類型Ordinary Share

年結日Feb 05

公司地址Emmy Noetherweg 2

城市LEIDEN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編2333 BK

電話31712036410

網址https://pharvaris.com/

公司代碼PHVS

上市日期Feb 05, 2021

CEOModig (Berndt B.A.E)

Pharvaris NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

1.63M

-1.57%

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

505.84K

--

Mr. David W. Nassif, J.D.

Chief Financial Officer

201.62K

+99.60%

Dr. David P. Meeker ,M.D.

Non-Executive Director

152.35K

+32.51%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

110.78K

+54.39%

Ms. Viviane Monges

Non-Executive Director

106.11K

+48.26%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.28K

-5.73%

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

--

Dr. Anne Lesage, Ph.D.

Co-Founder, Chief Early Development Officer

--

Dr. Morgan Conn, Ph.D.

Chief Business Officer

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

1.63M

-1.57%

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

505.84K

--

Mr. David W. Nassif, J.D.

Chief Financial Officer

201.62K

+99.60%

Dr. David P. Meeker ,M.D.

Non-Executive Director

152.35K

+32.51%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

110.78K

+54.39%

Ms. Viviane Monges

Non-Executive Director

106.11K

+48.26%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 2月19日週四

持股股東

股東類型

持股股東

佔比

General Atlantic LLC

11.53%

Fidelity Management & Research Company LLC

9.19%

Foresite Capital Management, LLC

6.86%

VenBio Partners LLC

6.66%

Viking Global Investors LP

5.24%

其他

60.52%

持股股東

佔比

General Atlantic LLC

11.53%

Fidelity Management & Research Company LLC

9.19%

Foresite Capital Management, LLC

6.86%

VenBio Partners LLC

6.66%

Viking Global Investors LP

5.24%

其他

60.52%

股東類型

持股股東

佔比

Private Equity

31.30%

Hedge Fund

20.13%

Investment Advisor

18.48%

Investment Advisor/Hedge Fund

10.17%

Venture Capital

4.94%

Individual Investor

4.89%

Research Firm

0.63%

Pension Fund

0.07%

Bank and Trust

0.07%

其他

9.33%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

165

59.26M

90.60%

-451.33K

2025Q4

152

61.74M

96.38%

+11.01M

2025Q3

118

49.64M

77.50%

-950.63K

2025Q2

125

52.21M

81.51%

-1.38M

2025Q1

125

53.89M

99.06%

+200.61K

2024Q4

123

53.45M

98.98%

+218.03K

2024Q3

114

53.86M

99.73%

+1.03M

2024Q2

83

52.08M

96.43%

-141.66K

2024Q1

76

49.63M

98.30%

-831.88K

2023Q4

69

47.76M

94.74%

+8.60M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

General Atlantic LLC

8.03M

12.54%

--

Dec 31, 2025

Fidelity Management & Research Company LLC

6.40M

9.99%

--

Dec 31, 2025

Foresite Capital Management, LLC

4.78M

7.46%

--

Dec 31, 2025

VenBio Partners LLC

4.64M

7.24%

--

Dec 31, 2025

Viking Global Investors LP

3.65M

5.7%

--

Dec 31, 2025

EQT Partners AB

3.42M

5.35%

--

Dec 31, 2025

Deerfield Management Company, L.P.

3.13M

4.88%

+683.58K

+27.99%

Dec 31, 2025

Bain Capital Life Sciences Investors, LLC

2.80M

4.37%

-379.19K

-11.92%

Dec 31, 2025

Wellington Management Company, LLP

1.91M

2.98%

+171.05K

+9.86%

Dec 31, 2025

Commodore Capital LP

1.89M

2.95%

-529.03K

-21.87%

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

0.87%

ALPS Medical Breakthroughs ETF

0.59%

iShares MSCI Netherlands ETF

0.23%

SPDR S&P International Small Cap ETF

0.08%

iShares MSCI Europe Small-Cap ETF

0.04%

iShares MSCI EAFE Small-Cap ETF

0.02%

Fidelity Nasdaq Composite Index ETF

0.01%

Xtrackers MSCI Eurozone Hedged Eqty ETF

0.01%

Avantis International Small Cap Equity ETF

0%

First Trust IPOX Europe Equity Opportunities ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.87%

ALPS Medical Breakthroughs ETF

佔比0.59%

iShares MSCI Netherlands ETF

佔比0.23%

SPDR S&P International Small Cap ETF

佔比0.08%

iShares MSCI Europe Small-Cap ETF

佔比0.04%

iShares MSCI EAFE Small-Cap ETF

佔比0.02%

Fidelity Nasdaq Composite Index ETF

佔比0.01%

Xtrackers MSCI Eurozone Hedged Eqty ETF

佔比0.01%

Avantis International Small Cap Equity ETF

佔比0%

First Trust IPOX Europe Equity Opportunities ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據